Devonian Health Group Updates on Thykamine Pipeline and Corrects Private Placement Details

Devonians Business Updates and Additional Details on the Last Declared Private Placement

Announcement

Devonian Health Group Inc., a leading clinical-stage corporation targeting the developing of different solutions for inflammatory disease, with the following corporate updates, including advancement to the companys pipeline with various fronts and additional information on the previous private placement.

Advancement on Numerous Fronts

On the manufacturing front, the constant involvement without skipping any batches of thykamine is validated via advanced analytical techniques consisting of quality leveraging performance of nuclear magnetic resonance (NMR) and liquid chromatography – mass spectrometry (HPLC-MS). The results of this procedure spotlight the powerful reliability and quality of the production process for this best-in-class therapeutic.

The pre-clinical programs are successive to further elaborate thykamines unique dual action on fibrosis and inflammation pathways. The recent studies in pulmonary fibrosis and metabolic-associated hepatitides (MASH) are introduced to mark its potency as a vastly applicable anti-fibrotic and anti-inflammatory drug. The readouts of the data might be declared this year and are expected to contribute extensive, various high-value indications.

Additionally, the company is working on the development of oral formulations (capsule and liquid) to disclose more opportunities in Ulcerative colitis and different diseases, specifically in oral delivery is in high demand. This diverse strategy expands thykamines market reach and powers its long-lasting marketing potential. The US survey of dermatologists verified the acceptance of thykamine cream in pediatric mild-to-moderate atopic dermatitis patients, which will help its marketing potential and clinical relevance.

Updates

As declared on 7th February 2025, the distribution license for dexlansoprazole had expired on 17th April 2025 and has not yet been renewed. The corporation was then informed that the distribution agreement of pantoprazole magnesium, a second product licensed from the same partner, will terminate on 23rd April 2026. The company will continue to sell and commercialize pantoprazole magnesium until that date, managing the revenue support in the interim. While the management is attentively evaluating the smart alternatives for this business structure.

On 7th August 2025, the corporation closed the non-brokered private placement for aggregate gross proceeds of $2,272,999.85. The corporation expects to further modify its press release to provide accurate information by making a few corrections to the last disclosed details related to the total gross proceeds that were previously stated as $2,272,999.85, which shows it was supposed to be $2,362,999.80 (the offering). The offering includes the issuance of 15,753,332 units and not 15,153,332 units of the corporation for $0.15 per unit. Every unit encompasses one common share of the corporation and one share purchase warrant. Every warrant is tied to the holder to purchase one share at a strike price of $0.20 per share for 24 months from the date of issuance.